We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
51
InflaRx
IFRX
$309M
$6.76M 0.04%
178,987
– –
FSTX
52
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.43M 0.04%
153,286
– –
BLUE
53
DELISTED
bluebird bio
BLUE
$6.29M 0.04%
3,088
– –
APLS
54
DELISTED
Apellis Pharmaceuticals
APLS
$6.12M 0.04%
313,725
+117,647
+60% +$1.85M
YARW
55
Yarrow Bioscience
YARW
$97.2M
$5.5M 0.04%
194
– –
MGNX icon
56
MacroGenics
MGNX
$261M
$5.44M 0.03%
+302,600
New +$5.23M
SYRS
57
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.25M 0.03%
57,484
– –
PTGX icon
58
Protagonist Therapeutics
PTGX
$9.99B
$5.08M 0.03%
+403,893
New +$3.57M
AUTL
59
Autolus Therapeutics
AUTL
$641M
$4.93M 0.03%
156,773
– –
HALO icon
60
Halozyme
HALO
$12.3B
$4.83M 0.03%
299,969
– –
VKTX icon
61
Viking Therapeutics
VKTX
$3.95B
$4.22M 0.03%
425,000
– –
FTSV
62
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$4.04M 0.03%
250,000
– –
XLRN
63
DELISTED
Acceleron Pharma
XLRN
$3.91M 0.03%
83,900
– –
ACOR
64
DELISTED
Acorda Therapeutics
ACOR
$3.88M 0.02%
+2,434
New +$4.38M
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.42M 0.02%
50,000
– –
LJPC
66
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.25M 0.02%
505,240
+350,565
+227% +$2.28M
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$3.24M 0.02%
1,095,359
– –
ARAV
68
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.03M 0.02%
430,885
+26,501
+7% +$138K
CRNX icon
69
Crinetics Pharmaceuticals
CRNX
$8.99B
$2.99M 0.02%
131,250
– –
LKFT
70
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$2.95M 0.02%
25,072
– –
ASMB icon
71
Assembly Biosciences
ASMB
$700M
$2.93M 0.02%
12,382
– –
CCXI
72
DELISTED
ChemoCentryx, Inc.
CCXI
$2.88M 0.02%
207,029
– –
YMAB
73
DELISTED
Y-mAbs Therapeutics
YMAB
$2.69M 0.02%
102,800
– –
ALKS icon
74
Alkermes
ALKS
$8.11B
$2.44M 0.02%
67,000
– –
ORTX
75
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.23M 0.01%
12,500
– –
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2019 Portfolio in Review

As of Q1 2019, Julian Baker held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Julian Baker added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Julian Baker's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Julian Baker fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Julian Baker's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Julian Baker opened 7 new positions and closed 4 in Q1 2019.
  • Julian Baker's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.